Cameron Santoro

Sarah Hogue, PharmD, director of oncology services at St. Luke's Cancer Institute, discusses trends of pharmacists and technicians taking on more clinical responsibilities in oncology, improving patient care, and efficiency.

Mammography facilities are now nationally required to inform patients about their breast density, which can affect cancer detection.

Samyukta Mullangi, MD, MBA, medical director at Thyme Care, explained her excitement to meet with industry leaders, share best practices, and learn about new innovations in oncology care at Patient-Centered Oncology Care® (PCOC) 2024.

Kristen Whitney, DO, FAAD, determines systemic treatment options for severe alopecia areata based on the patient’s medical history, past treatments tried, potential adverse events, in addition to the weighing risk vs benefit of the therapy and the cost for the patient.

Susan Sabo-Wagner, MSN, RN, OCN, of the American Oncology Network, expressed excitement toward networking, innovative discussions, and panels on patient advocacy at Patient-Centered Oncology Care® (PCOC) 2024.

Using artificial intelligence (AI) in breast cancer screenings in the United Kingdom could be cost-effective and improve health outcomes after identifying more cancers.

Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while new drugs promise to slow the disease and improve patients’ lives.

Kristen Whitney, DO, FAAD, dermatologist within the Allegheny Health Network, discusses advancements in dermoscopy, predicting that emerging technologies and artificial intelligence (AI) will improve dermatologists' efficiency in monitoring and diagnosing skin conditions.

Patients with alopecia areata have a significantly increased risk of developing psychiatric and autoimmune diseases both before and after diagnosis, highlighting the importance of comprehensive care for these individuals.

There is a critical need for improved athlete care as rising injury rates demand greater investment in prevention and support.

A new review highlights the urgent need for research-driven solutions in breast cancer to enhance early detection, treatment, and patient support across diverse populations.

A bibliometric analysis reveals a significant increase in research on alopecia areata treatment over the past 2 decades, with a focus on identifying effective therapies and understanding underlying mechanisms of the condition.

Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.

The FDA has approved axatilimab-csfr (Niktimvo) for treating adults and children with chronic graft-versus-host disease who have progressed on at least 2 prior treatments.

CMS today announced the agreed-upon lower prices for all 10 drugs selected for price negotiations under the Inflation Reduction Act.

Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery.

Artificial intelligence (AI) can aid in breast cancer detection, but radiologists need training to ensure accuracy and prevent missed cancers.

Autologous fat grafting offers hope for patients with alopecia, especially those with scarring, by reducing inflammation and stimulating hair growth.

Harold "Hal" Burstein, MD, PhD, emphasizes the crucial role of strong patient-physician partnerships in breast cancer treatment, empowering patients through shared decision-making.

Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women's Hospital, discusses the recent FDA approval of deuruxolitinib for the treatment of moderate to severe alopecia areata.

Despite the development of life-saving vaccines, the resurgence of preventable diseases highlights the ongoing challenges posed by misinformation, resource disparities, and global health inequities.

Accessia Health works with advocacy groups to understand specific needs, such as travel assistance, affordable care, and diagnostic testing, ensuring a personalized and human-centered approach to health equity.

The COVID-19 pandemic disrupted breast cancer screenings, leading to decreased follow-up rates and widening health disparities.

Trusted community organizations can effectively communicate and connect underserved populations to necessary health services, Tiara Green, MSEd, Accessia Health says in an interview.

Posters presented at the Society for Pediatric Dermatology Annual Meeting shed new light on pediatric hair loss, including the rising prevalence of androgenetic alopecia in children, the potential of artificial intelligence to assess hair loss severity, and the long-term safety of ritlecitinib for treating alopecia areata in adolescents.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.

The risk of early-onset breast cancer, particularly luminal A and triple-negative subtypes, was higher in Black women with obesity and high leptin levels compared with White women. This research highlights the urgent need for targeted interventions to address racial disparities in breast cancer outcomes.

The FDA has approved deuruxolitinib, an oral medication developed by Sun Pharma, as the first-line treatment for adults with moderate to severe alopecia areata.

Health care inequity is costing the United States billions of dollars without providing quality outcomes for patients with rare and chronic diseases, Tiara Green, MSEd, president of Accessia Health, tells The American Journal of Managed Care.